https://www.facebook.com/insnewsnetinsnewsnet
doi:info:doi/10.1016/0924-977X(96)87389-5Unterbeck, AEuropean NeuropsychopharmacologyA. Unterbeck. Pharamaceutical research and development activities in Alzheimerus disease, Eur. Neuropsychopharmacol. 6: 20 (1996).
Bermuda-based biotech Roivant Neurosciences has licensed rights to an Alzheimer's disease candidate developed by GlaxoSmithKline (GSK) and is planning to start pivotal trials in 2015. The drug in question - called SB742457 - is a selective...Linda Banks...